Archive
Oct 5, 2023
These slides contain the 60-week and 2-year (96-weeks) results from the Phase 3 PULSAR study of aflibercept 8 mg for nAMD. The presentation was given by Dr. Paolo Lanzetta at the 23rd EURETINA Congress on October 5, 2023.
Sep 11, 2023 9:20 AM EDT
Sep 6, 2023 8:45 AM EDT
Aug 3, 2023 8:30 AM EDT
Jul 29, 2023
These slides contain the 2-year (96 weeks) results from the Phase 2/3 PHOTON study of aflibercept 8 mg for DME. The presentation was given by Diana V. Do, MD at the American Society of Retina Specialists Annual Meeting on July 29, 2023.
Jun 14, 2023 11:40 AM EDT
Jun 9, 2023 10:30 AM EDT
2023 Annual Meeting of Shareholders
The 2023 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. will be held on Friday, June 9, 2023, commencing at 10:30 a.m., Eastern Time, virtually via the Internet at www.virtualshareholdermeeting.com/REGN2023.
Jun 7, 2023 8:30 AM EDT
May 30, 2023 12:30 PM EDT